Clinical News

Baricitinib Plus Remdesivir Improves Recovery Time for Hospitalized COVID-19

September 15, 2020

Early data from a phase 3 trial showed that baricitinib combined with remdesivir improved recovery in patients hospitalized with COVID-19 compared with remdesivir alone.

FDA Alert: Efficacy Concerns with Atezolizumab Plus Paclitaxel for Breast Cancer

September 11, 2020

The FDA issued a safety alert about efficacy and potential safety concerns with a combination therapy being studied for the treatment of breast cancer.

FDA OKs Azacitidine Tablets for Acute Myeloid Leukemia

September 03, 2020

Oral azacitidine (Onureg; Celgene) is approved for patients in first remission with acute myeloid leukeimia.

ACIP Updates Flu Vaccine Recommendations for 2020-2021 Season

August 25, 2020

Primary updates to the guidance includes the composition of the 2020-2021 flu vaccines and the recent licensures of 2 new influenza vaccines.

FDA OKs Risdiplam for Treatment of Spinal Muscular Atrophy

August 07, 2020

Risdiplam (Evrysdi; Genentech) is the only SMA therapy that can be administered at home.

FDA OKs New Indication for Esketamine Nasal Spray

August 05, 2020

Esketamine (Spravato; Janssen) CIII nasal spray is the first FDA-approved antidepressant medication that improves depressive symptoms with the first dose in adults with major depressive disorder.

International Panel Issues Weak Recommendation for Remdesivir in Severe COVID-19

August 03, 2020

A panel has given a “weak recommendation” for the use of remdesivir in patients with severe coronavirus disease 2019.

Empagliflozin Reduces Heart Failure Hospitalization, Death Risk in Phase 3 Trial

July 31, 2020

Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.

Moderna’s COVID-19 Vaccine Candidate Shows Safety, Immune Response Results in Phase 1 Study

July 15, 2020

Moderna announced interim analysis results of its investigational COVID-19 vaccine candidate, mRNA-1273, from an ongoing phase 1 study.

FDA Approves Fostemsavir for Heavily Pretreated Patients With HIV

July 03, 2020

Fostemsavir (Rukobia, ViiV Healthcare) is indicated for use in heavily treatment-experienced adults with multidrug resistant HIV-1 infection.